← FDA DRUG APPROVALS

FDA ANDA · ANDA204928

ZAFIRLUKAST

Sponsor: RISING PHARMS

APPLICATION
ANDA204928
TYPE
ANDA
ORIGINAL APPROVAL
2022-08-25
LATEST ACTION
2022-08-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ZAFIRLUKASTPrescription
ZAFIRLUKAST 10MG · TABLET · ORAL
ZAFIRLUKASTPrescription
ZAFIRLUKAST 20MG · TABLET · ORAL

Approval history

2022-08-25UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →